Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Drug-eluting stents (DES) are associated with rare but catastrophic stent thrombosis.
• Current dual antiplatelet therapy (DAPT) with aspirin and clopidogrel may not be adequate for all patients.
• Patient adherence to antiplatelet therapy is a significant clinical challenge.

Purpose of the Study:

• To evaluate the adequacy of current DAPT regimens following DES deployment.
• To explore alternative antiplatelet strategies for patients at high risk of stent thrombosis.
• To highlight the challenges in ensuring patient adherence to antiplatelet therapy.

Main Methods:

• Review of clinical observations and literature regarding stent thrombosis and antiplatelet therapy.
• Discussion of the role of glycoprotein (GP) IIb/IIIa inhibitors in specific patient populations.
• Analysis of factors contributing to premature discontinuation of antiplatelet therapy.

Main Results:

• Some patients exhibit inadequate response to clopidogrel, necessitating alternative treatments.
• Glycoprotein IIb/IIIa inhibitors may be beneficial for high-risk patients or those not pretreated with clopidogrel.
• Reasons for non-adherence to antiplatelet therapy are diverse, including cost, bleeding, and surgical needs.

Conclusions:

• The current DAPT regimen requires careful consideration in the context of DES implantation.
• Glycoprotein IIb/IIIa inhibitors represent a potential adjunct therapy for selected high-risk patients.
• Ensuring adherence to antiplatelet therapy is a critical and evolving aspect of post-stenting care.